Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$4.3 million.

  • Atara Biotherapeutics' Net Income towards Common Stockholders rose 8035.97% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.4 million, marking a year-over-year increase of 11754.08%. This contributed to the annual value of -$85.4 million for FY2024, which is 6909.89% up from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Net Income towards Common Stockholders is -$4.3 million, which was up 8035.97% from $2.4 million recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year Net Income towards Common Stockholders high stood at $38.0 million for Q1 2025, and its period low was -$88.1 million during Q1 2022.
  • Over the past 4 years, Atara Biotherapeutics' median Net Income towards Common Stockholders value was -$31.8 million (recorded in 2024), while the average stood at -$36.9 million.
  • As far as peak fluctuations go, Atara Biotherapeutics' Net Income towards Common Stockholders plummeted by 48507.53% in 2023, and later skyrocketed by 21970.9% in 2025.
  • Atara Biotherapeutics' Net Income towards Common Stockholders (Quarter) stood at -$74.7 million in 2022, then grew by 18.72% to -$60.7 million in 2023, then skyrocketed by 79.09% to -$12.7 million in 2024, then skyrocketed by 66.1% to -$4.3 million in 2025.
  • Its Net Income towards Common Stockholders was -$4.3 million in Q3 2025, compared to $2.4 million in Q2 2025 and $38.0 million in Q1 2025.